ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,267.84
-0.74%
Dow Jones
39,065.26
-1.53%
US Dollar vs MXN
16.7222
0.35%
Brent Oil
81.31
-0.27%
Bitcoin
67,741.27
-1.97%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. CytomX Therapeutics Inc (CTMX)

  7. CytomX Therapeutics Inc (CTMX) Noticias

CTMX

CytomX Therapeutics (CTMX)

CytomX Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:CTMX
FechaHoraFuenteTítuloSímboloCompañía
22/05/202415:05GlobeNewswire Inc.CytomX Therapeutics to Present at the Jefferies Global Healthcare ConferenceNASDAQ:CTMXCytomX Therapeutics Inc
17/05/202416:36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTMXCytomX Therapeutics Inc
17/05/202415:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTMXCytomX Therapeutics Inc
16/05/202415:15GlobeNewswire Inc.CytomX Therapeutics Announces New Employment Inducement GrantsNASDAQ:CTMXCytomX Therapeutics Inc
13/05/202415:00Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CTMXCytomX Therapeutics Inc
08/05/202415:10GlobeNewswire Inc.CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:CTMXCytomX Therapeutics Inc
08/05/202415:10GlobeNewswire Inc.CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)NASDAQ:CTMXCytomX Therapeutics Inc
08/05/202415:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CTMXCytomX Therapeutics Inc
07/05/202415:15GlobeNewswire Inc.CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)NASDAQ:CTMXCytomX Therapeutics Inc
01/05/202407:00GlobeNewswire Inc.CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024NASDAQ:CTMXCytomX Therapeutics Inc
08/04/202407:00GlobeNewswire Inc.CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid TumorsNASDAQ:CTMXCytomX Therapeutics Inc
03/04/202407:00GlobeNewswire Inc.CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with AstellasNASDAQ:CTMXCytomX Therapeutics Inc
21/03/202407:00GlobeNewswire Inc.CytomX Therapeutics Appoints Dr. Zhen Su to Board of DirectorsNASDAQ:CTMXCytomX Therapeutics Inc
18/03/202407:00GlobeNewswire Inc.CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with AstellasNASDAQ:CTMXCytomX Therapeutics Inc
11/03/202415:30Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CTMXCytomX Therapeutics Inc
11/03/202415:10GlobeNewswire Inc.CytomX Therapeutics Reports 2023 Financial Results and Provides Business UpdateNASDAQ:CTMXCytomX Therapeutics Inc
11/03/202415:00Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:CTMXCytomX Therapeutics Inc
11/03/202405:39IH Market NewsU.S. Index Futures Dip Ahead of Inflation Data and Oracle’s Earnings; Oil Prices Edge HigherNASDAQ:CTMXCytomX Therapeutics Inc
04/03/202407:00GlobeNewswire Inc.CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024NASDAQ:CTMXCytomX Therapeutics Inc
27/02/202407:00GlobeNewswire Inc.CytomX Therapeutics to Present at Upcoming March Investor ConferencesNASDAQ:CTMXCytomX Therapeutics Inc
24/01/202407:00GlobeNewswire Inc.CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2bNASDAQ:CTMXCytomX Therapeutics Inc
12/01/202407:00GlobeNewswire Inc.CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology ConferenceNASDAQ:CTMXCytomX Therapeutics Inc
04/01/202407:00GlobeNewswire Inc.CytomX Therapeutics Outlines 2024 Company Priorities and MilestonesNASDAQ:CTMXCytomX Therapeutics Inc
21/12/202307:00GlobeNewswire Inc.CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:CTMXCytomX Therapeutics Inc
07/11/202315:15GlobeNewswire Inc.CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:CTMXCytomX Therapeutics Inc
01/11/202307:00GlobeNewswire Inc.CytomX Therapeutics to Present at Upcoming November Investor ConferencesNASDAQ:CTMXCytomX Therapeutics Inc
31/10/202307:00GlobeNewswire Inc.CytomX Therapeutics to Report Third Quarter 2023 Financial Results on November 7, 2023NASDAQ:CTMXCytomX Therapeutics Inc
30/10/202307:00GlobeNewswire Inc.CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b at the SITC 2023 Annual MeetingNASDAQ:CTMXCytomX Therapeutics Inc
18/10/202315:30GlobeNewswire Inc.CytomX Therapeutics Presents Preclinical Profile of EpCAM-directed Antibody Drug Conjugate CX-2051 at 2023 World ADC ConferenceNASDAQ:CTMXCytomX Therapeutics Inc
05/09/202315:05GlobeNewswire Inc.CytomX Therapeutics to Present at Upcoming September Investor ConferencesNASDAQ:CTMXCytomX Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CTMX

Su Consulta Reciente

BIT
P1Z6K8
NLBNPIT1Z6K8 20991231 14...
TSX
HFPC.U
Helios Fairfax Partners
BIT
F30351
Vontobel Financial Produ...
BIT
MU
Micron Technology
BIT
UB26GT
UniCredit Bank
BIT
P19KB0
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados